Prostate Cancer – Pipeline Insight, 2020
This report can be delivered to the clients within 5 Business days
DelveInsight’s, “Prostate Cancer – Pipeline Insight, 2020,” report provides comprehensive insights about 900+ companies and 900+ pipeline drugs in Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Prostate Cancer: Overview
The prostate is a small walnut shaped gland in the pelvis of men. It is located next to the bladder and can be examined by getting a digital rectal exam. Prostate cancer is a form of cancer that develops in the prostate gland. It is the second-leading cause of cancer deaths for men in the U.S. About 1 in 9 men will be diagnosed with prostate cancer in their lifetime. This year, nearly 191,000 men will be diagnosed with prostate cancer. Growths in the prostate can be benign (not cancer) or malignant (cancer).
Benign growths (like benign prostatic hyperplasia (BPH):
Treatment
Primarily, surgery, radiation therapy, and proton beam therapy are the current treatment options of prostate cancer. However, chemotherapy, hormonal therapy, cryosurgery, and high intensity focused ultrasound (HIFU) are also belonging to the treatment strategies, depending on clinical conditions, and outcomes. Also, the choice of treatment depends on the stages of the disease progression, the level of prostate specific antigen (PSA), the Gleason score among others.
Prostate Cancer Emerging Drugs Chapters
This segment of the Prostate Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Prostate Cancer Emerging Drugs
Prostate Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Prostate Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Prostate Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Prostate Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prostate Cancer drugs.
Report Highlights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Prostate Cancer – Pipeline Insight, 2020,” report provides comprehensive insights about 900+ companies and 900+ pipeline drugs in Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Prostate Cancer: Overview
The prostate is a small walnut shaped gland in the pelvis of men. It is located next to the bladder and can be examined by getting a digital rectal exam. Prostate cancer is a form of cancer that develops in the prostate gland. It is the second-leading cause of cancer deaths for men in the U.S. About 1 in 9 men will be diagnosed with prostate cancer in their lifetime. This year, nearly 191,000 men will be diagnosed with prostate cancer. Growths in the prostate can be benign (not cancer) or malignant (cancer).
Benign growths (like benign prostatic hyperplasia (BPH):
- Are rarely a threat to life
- Don't invade the tissues around them
- Don't spread to other parts of the body
- Can be removed and can grow back very slowly (but usually don't grow back)
- May sometimes be a threat to life
- Can spread to nearby organs and tissues (such as the bladder or rectum)
- Can spread (metastasize) to other parts of the body (like lymph nodes or bone)
- Often can be removed but sometimes grow back
Treatment
Primarily, surgery, radiation therapy, and proton beam therapy are the current treatment options of prostate cancer. However, chemotherapy, hormonal therapy, cryosurgery, and high intensity focused ultrasound (HIFU) are also belonging to the treatment strategies, depending on clinical conditions, and outcomes. Also, the choice of treatment depends on the stages of the disease progression, the level of prostate specific antigen (PSA), the Gleason score among others.
Prostate Cancer Emerging Drugs Chapters
This segment of the Prostate Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Prostate Cancer Emerging Drugs
- Relugolix: Myovant
- FP-001: Foresee Pharmaceuticals
- LMIS 50 mg: Pre-registration stage (Foresee Pharmaceuticals submitted NDA for FDA approval of LMIS 50 mg)
- LMIS 25 mg: Phase III Stage
- LMIS 8.3 mg: Research Stage
- GX301: Mediolanum
- TAS3681: Taiho Oncology
- A selective AR antagonist suppressing transactivation of both wild-type and mutated (including F876L) cell lines and inhibiting AR translocation to the nucleus
- Downregulating AR expression in prostate cancer cells in vitro and in vivo and effectively suppressing androgen independent AR transactivation by outlaw pathways
- Driving AR downregulation of full-length androgen receptor (FL-AR) and AR splice variants (eg, AR-v7) in vitro and in vivo, and suppressing AR dependent and AR-v7 dependent cell growth
Prostate Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Prostate Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Prostate Cancer
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
Prostate Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Prostate Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Prostate Cancer drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Prostate Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Prostate Cancer.
- A New Drug Application (NDA) has been submitted to the FDA for once-daily, oral relugolix (RRVT-601, Relumina) at a dose of 120 mg as treatment of male patients with advanced prostate cancer by the company.
- Takeda has granted Myovant an exclusive, worldwide license (excluding Japan and certain other Asian countries) to relugolix (TAK-385). Takeda will retain commercial rights for relugolix in Asian countries, including Japan, where is actively conducting two phase 3 registration studies for the treatment of uterine fibroids.
- March 2019: Foresee Pharmaceuticals announces submission of NDA for FDA approval of LMIS 50 mg
- Prostate Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Prostate Cancer drugs?
- How many Prostate Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Prostate Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Prostate Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Prostate Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- AstraZeneca
- Daiichi Sankyo
- Abgenix
- Orion Corporation
- Pfizer
- Bayer
- Medivation LLC
- Clovis Oncology
- Laekna Limited
- FutureChem
- Foresee Pharmaceuticals
- Mediolanum
- Myovant
- Taiho Oncology
- Capivasertib
- PLX3397
- ABX-EGF
- ODM-201
- Enzalutamide
- BAY1841788
- MDV3100
- Rucaparib
- LAE001
- Ludotadipep
- FP-001
- GX301
- Relugolix
- TAS3681
Introduction
Executive Summary
Prostate Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Prostate Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Prostate Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Prostate Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III and Preregistration)
Comparative Analysis
Relugolix: Myovant
Product Description
Research and Development
Product Development Activities
FP-001: Foresee Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
GX301: Mediolanum
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TAS3681: Taiho Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Prostate Cancer Key Companies
Prostate Cancer Key Products
Prostate Cancer- Unmet Needs
Prostate Cancer- Market Drivers and Barriers
Prostate Cancer- Future Perspectives and Conclusion
Prostate Cancer Analyst Views
Prostate Cancer Key Companies
Appendix
Executive Summary
Prostate Cancer: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Prostate Cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Prostate Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Prostate Cancer Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III and Preregistration)
Comparative Analysis
Relugolix: Myovant
Product Description
Research and Development
Product Development Activities
FP-001: Foresee Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
GX301: Mediolanum
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TAS3681: Taiho Oncology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
Prostate Cancer Key Companies
Prostate Cancer Key Products
Prostate Cancer- Unmet Needs
Prostate Cancer- Market Drivers and Barriers
Prostate Cancer- Future Perspectives and Conclusion
Prostate Cancer Analyst Views
Prostate Cancer Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Prostate Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Prostate Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Prostate Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Prostate Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products